Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloromethane SCHEMBL28895816 | 0.97 | MEN1 (0.41) | MEN1GAAKMT2ADGAT1TDP1 | |
| SCHEMBL101218 | 0.86 | DGAT1 (0.46) | MEN1GAAKMT2ADGAT1TDP1 | |
| SCHEMBL15553702 | 0.84 | MEN1 (0.37) | MEN1GAAKMT2ADGAT1TDP1 | |
| SCHEMBL15756433 | 0.84 | GAA (0.40) | MEN1GAAKMT2ADGAT1TDP1 | |
| Potassium SCHEMBL29554503 | 0.83 | DGAT1 (0.44) | MEN1GAAKMT2ADGAT1TDP1 | |
| SCHEMBL6272856 | 0.83 | DGAT1 (0.44) | MEN1GAAKMT2ADGAT1TDP1 | |
| SCHEMBL1522412 | 0.83 | DGAT1 (0.44) | MEN1GAAKMT2ADGAT1TDP1 | |
| SCHEMBL27506147 | 0.82 | MEN1 (0.41) | MEN1GAAKMT2ADGAT1TDP1 | |
| SCHEMBL14949475 | 0.81 | DGAT1 (0.42) | MEN1GAAKMT2ADGAT1TDP1 | |
| SCHEMBL12513316 | 0.80 | KDM5B (0.46) | MEN1GAAKMT2ADGAT1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694524-B1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | US HEALTH (US) | 2016-05-18 | — | — | EP | claimed |
| US-9284343-B2 | 2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-15 | — | — | US | claimed |
| EP-2820051-A1 | DERIVATES BASED ON HYALURONIC ACID, CAPABLE OF FORMING HYDROGELS, METHOD OF PREPARATION THEREOF, HYDROGELS BASED ON SAID DERIVATIVES, METHOD OF PREPARATION THEREOF AND USE | Contipro Biotech s.r.o. (CZ) | 2015-01-07 | — | — | EP | claimed |
| US-20140051846-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | TheUnited ofAmerica,asrepresentedbythe Secre -tary,Department ofHealthand Human Service (US) | 2014-02-20 | — | — | US | claimed |
| EP-2694524-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2013127374-A1 | DERIVATES BASED ON HYALURONIC ACID, CAPABLE OF FORMING HYDROGELS, METHOD OF PREPARATION THEREOF, HYDROGELS BASED ON SAID DERIVATIVES, METHOD OF PREPARATION THEREOF AND USE | CONTIPRO BIOTECH S.R.O. (CZ) | 2013-09-06 | — | — | WO | claimed |
| WO-2012138530-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-10-11 | — | — | WO | claimed |
| EP-1248612-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-09-07 | — | — | EP | claimed |
| EP-1248612-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2002-10-16 | — | — | EP | claimed |
| WO-2001049288-A9 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2001-10-25 | — | — | WO | claimed |
| WO-2001049288-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-07-12 | — | — | WO | claimed |
| US-12636371-B2 | Chemically coupled transporter for low-hydrophobicity bioactive drugs into the central nervous system | SKYBIO LLC (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-4652171-A1 | TOTAL SYNTHESES OF PORTIMINE A AND ANALOGUES THEREOF AS SMALL MOLECULE MODULATORS OF NMD3 | The Scripps Research Institute (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | UNIVERSITE DE MONTREAL (CA) | 2025-11-25 | — | — | US | disclosed |
| CN-1212705-A | Serine protease inhibitors | AKZO NOBEL NV (NL) | 1999-03-31 | — | — | CN | disclosed |
| WO-1998015278-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-16 | — | — | WO | disclosed |
| WO-1998014192-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-09 | — | — | WO | disclosed |
| WO-1997047194-A1 | SUBSTITUTED CYCLOPENTANE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-12-18 | — | — | WO | disclosed |
| WO-1997031939-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, DPYD | MEN1 1888/4885GAA 2625/4885KMT2A 2305/4885 |
| US-12636371-B2 | Chemically coupled transporter for low-hydrophobicity bioactive drugs into the central nervous system | SLC6A2, SLC6A3, SLC18A2 | MEN1 2497/4885GAA 605/4885KMT2A 2876/4885 |
| US-20140051846-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | NSUN2, RNGTT, RNMT | MEN1 1919/4885GAA 3844/4885KMT2A 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.